With the expectation that most patients with anti-GAD cerebellar ataxia will accumulate significant disability [12], consideration is often given to immunosuppression despite the lack of evidence from placebo-controlled trials [13]. This evidence concerns the gene GAD1 and cerebellar ataxia.